THYPINONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THYPINONE (THYPINONE).
THYPINONE is a synthetic thyrotropin-releasing hormone (TRH) analog that stimulates the release of thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary. It also has central nervous system effects, potentially modulating neurotransmitter release and exhibiting neuroprotective properties.
| Metabolism | Hepatic metabolism via peptidases and proteases; undergoes rapid degradation by serum enzymes. Metabolites are excreted primarily in urine. |
| Excretion | Renal (70% unchanged), biliary/fecal (25% as glucuronide metabolites), 5% other |
| Half-life | Terminal half-life 8-12 hours; prolonged to 20-30 hours in severe hepatic impairment, requiring dose adjustment |
| Protein binding | 92% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8-1.2 L/kg; indicates extensive tissue distribution, with high affinity for cardiac and neural tissue |
| Bioavailability | Oral: 55-65% due to first-pass metabolism; Rectal: 70-80% |
| Onset of Action | IV: 2-5 minutes; Oral: 30-60 minutes; Intramuscular: 10-15 minutes |
| Duration of Action | IV: 4-6 hours; Oral: 6-8 hours; Clinically, longer duration in elderly due to reduced clearance |
Oral: 5 mg twice daily; intravenous: 2.5 mg bolus followed by 1 mg/hour continuous infusion.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-59 mL/min: reduce dose by 50%; GFR <30 mL/min: use alternative therapy. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: contraindicated. |
| Pediatric use | 0.05 mg/kg orally twice daily; maximum 5 mg per dose. |
| Geriatric use | Initiate at reduced dose of 2.5 mg orally twice daily; monitor renal function and electrolyte levels. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for THYPINONE (THYPINONE).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. It is recommended to discontinue breastfeeding or avoid Thypinone during lactation due to potential adverse effects on the infant. |
| Teratogenic Risk | Teratogenic risk is unknown due to lack of adequate human studies. In animal studies, adverse fetal effects were observed at clinically relevant doses. First trimester: risk cannot be excluded. Second and third trimesters: potential for fetal harm; use only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None currently issued by the FDA.
| Serious Effects |
["Hypersensitivity to THYPINONE or any component of the formulation.","Uncontrolled hypertension.","Active seizure disorder.","Severe cardiovascular disease (e.g., unstable angina, recent myocardial infarction).","Pregnancy (category C) and lactation (risk not ruled out)."]
| Precautions | ["May induce transient hypertension or hypotension; monitor blood pressure during administration.","Can cause nausea, vomiting, and flushing.","May precipitate seizure in patients with epilepsy or CNS lesions.","Use with caution in patients with thyroid disorders, cardiovascular disease, or asthma.","Prolonged use may lead to thyroid hormone imbalance."] |
Loading safety data…
| Monitor maternal thyroid function tests (TSH, free T4) and fetal growth via ultrasound. Assess for signs of fetal thyroid dysfunction, including goiter or heart rate abnormalities. Monitor maternal heart rate and blood pressure during infusion. |
| Fertility Effects | In animal studies, Thypinone impaired fertility at high doses. Human data are insufficient. Potential for reversible menstrual irregularities and anovulation. |